Comparison of acquisition time and dose for late gadolinium enhancement imaging at 3.0 T in patients with chronic myocardial infarction using Gd-BOPTA

[1] Hundley WG(2010)ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents J Am Coll Cardiol 55 2614-2662

[2] Bluemke DA(2013)European Cardiovascular Magnetic Resonance (EuroCMR) registry—multi national results from 57 centers in 15 countries J Cardiovasc Magn Reson 15 9-667

[3] Finn JP(2006)Assessment of myocardial viability using delayed enhancement magnetic resonance imaging at 3.0 Tesla Invest Radiol 41 661-1131

[4] Bruder O(2009)Intraindividual comparison of myocardial delayed enhancement MR imaging using gadobenate dimeglumine at 1.5 T and 3 T Eur Radiol 19 1124-637

[5] Wagner A(2008)Performance of delayed-enhancement magnetic resonance imaging with gadoversetamide contrast for the detection and assessment of myocardial infarction: an international, multicenter, double-blinded, randomized trial Circulation 117 629-2033

[6] Lombardi M(2006)Effects of time, dose, and inversion time for acute myocardial infarct size measurements based on magnetic resonance imaging-delayed contrast enhancement J Am Coll Cardiol 47 2027-883

[7] Klumpp B(2007)Safety update on the possible causal relationship between gadolinium-containing MRI agents and nephrogenic systemic fibrosis J Magn Reson Imaging 25 881-668

[8] Fenchel M(2007)What nephrologists need to know about gadolinium Nat Clin Pract Nephrol 3 654-251

[9] Hoevelborn T(1970)Time saving measurement of NMR and EPR relaxation times Rev Sci Instrum 41 250-156

[10] Klumpp BD(2011)Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance JACC Cardiovasc Imaging 4 150-457

[1] Hundley WG(2010)ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents J Am Coll Cardiol 55 2614-2662

[2] Bluemke DA(2013)European Cardiovascular Magnetic Resonance (EuroCMR) registry—multi national results from 57 centers in 15 countries J Cardiovasc Magn Reson 15 9-667

[3] Finn JP(2006)Assessment of myocardial viability using delayed enhancement magnetic resonance imaging at 3.0 Tesla Invest Radiol 41 661-1131

[4] Bruder O(2009)Intraindividual comparison of myocardial delayed enhancement MR imaging using gadobenate dimeglumine at 1.5 T and 3 T Eur Radiol 19 1124-637

[5] Wagner A(2008)Performance of delayed-enhancement magnetic resonance imaging with gadoversetamide contrast for the detection and assessment of myocardial infarction: an international, multicenter, double-blinded, randomized trial Circulation 117 629-2033

[6] Lombardi M(2006)Effects of time, dose, and inversion time for acute myocardial infarct size measurements based on magnetic resonance imaging-delayed contrast enhancement J Am Coll Cardiol 47 2027-883

[7] Klumpp B(2007)Safety update on the possible causal relationship between gadolinium-containing MRI agents and nephrogenic systemic fibrosis J Magn Reson Imaging 25 881-668

[8] Fenchel M(2007)What nephrologists need to know about gadolinium Nat Clin Pract Nephrol 3 654-251

[9] Hoevelborn T(1970)Time saving measurement of NMR and EPR relaxation times Rev Sci Instrum 41 250-156

[10] Klumpp BD(2011)Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance JACC Cardiovasc Imaging 4 150-457